How Oracle Stock Rises To $300

Oracle is presented as having a plausible path to $300-$330 per share by 2028, driven by revenue growth from $64.08B TTM to a projected $108.0B and adjusted EPS rising to over $11. The bullish case hinges on OCI backlog conversion, data center buildouts, and AI training workload demand, despite near-term margin pressure from heavy capex. The article also implies valuation upside if Oracle re-rates toward its 3-year average 30x P/E multiple.

Analysis

Oracle is not really an earnings story; it is a capital-intensity conversion story. The market is paying today for a future where backlog turns into visible cash flow, but the key second-order effect is that every incremental dollar of OCI revenue likely arrives with a temporarily distorted margin structure because the company is still front-loading GPU, power, and data-center commitments. That means the stock’s path is less about linear EPS growth and more about when investors decide the capex peak is behind them and attach a scarcity premium to available AI infrastructure capacity.

The competitive implication is more interesting than the headline target. If Oracle keeps winning training workloads, the pressure is not just on IBM’s legacy stack; it also forces hyperscalers to defend share with lower pricing or richer incentives, which could spill into cloud margin pressure across the group. Conversely, the real bottleneck is upstream: networking gear, power equipment, and specialized chip allocation can become the choke points that determine whether Oracle’s revenue ramp is smooth or lumpy over the next 6-18 months.

The consensus risk is that investors are extrapolating the multiple re-rating before the operating proof arrives. If backlog conversion slows, or if supply chain constraints delay capacity delivery, the market will likely compress the multiple first and ask questions later, even if the medium-term demand thesis remains intact. The more likely near-term setup is choppy price action with upside on capacity milestones and downside on any quarter that shows capex intensity rising faster than revenue monetization.

The contrarian angle is that the upside may be real but not uniquely underwritten by Oracle alone: the better risk-adjusted expression could be the picks-and-shovels beneficiaries of the AI buildout, where revenue is less dependent on flawless backlog execution. Oracle still has room to rerate, but at current levels the trade is increasingly about confidence in execution cadence rather than valuation cheapness.

Key Decisions for Investors

• Long ORCL on pullbacks over the next 1-3 months, but size it as a catalyst trade rather than a core position; target a 12-18 month move toward the low-$200s first, with upside to $300 only if backlog conversion and capacity milestones stay on schedule.
• Pair trade: long ORCL / short IBM for 6-12 months. ORCL has the cleaner AI-capacity monetization path, while IBM is more exposed to slower-growth legacy mix; this isolates cloud infrastructure adoption relative to legacy enterprise IT.
• Prefer a basket long in AI infrastructure enablers over a pure ORCL bet: consider semis/networking/power names that benefit from capex regardless of end-customer pricing power. This lowers execution risk versus owning the platform operator alone.
• Use ORCL call spreads rather than outright stock for the next earnings cycle if implied vol is reasonable; this captures re-rating potential while limiting downside if capex commentary triggers margin concerns.
• If ORCL fails to show backlog-to-revenue conversion acceleration in the next 1-2 quarters, fade the multiple expansion thesis and rotate out; that would likely be the earliest signal that the $300 path is getting deferred rather than denied.